Jazz Pharmaceuticals plc
Moat Score — Jazz Pharmaceuticals plc
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Jazz holds patents and orphan-drug/regulatory exclusivity across Xywav, Epidiolex, Rylaze, and Zepzelca, and Epidiolex's ANDA litigation settlements push generic entry out to the late 2030s in most cases, giving Jazz an unusually long legally-defined exclusivity runway for a specialty pharma. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Jazz is not a low-cost manufacturer; its economics come from rare-disease pricing power rather than any structural cost edge, and running a dedicated REMS central-pharmacy distribution network for oxybates is actually a cost burden Jazz accepts in exchange for distribution control. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | As the primary or only approved treatment for several rare conditions (idiopathic hypersomnia, specific pediatric epilepsy syndromes, ALL/LBL needing erwinia asparaginase), Jazz can command premium specialty-drug pricing, reflected in Xywav and Epidiolex together driving roughly two-thirds of a record $4.3 billion 2025 revenue base. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Jazz's products are chronic or acute therapies prescribed one patient at a time; no product becomes more effective or valuable as more patients or physicians adopt it, so there is no network dynamic at work. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Patients stabilized on nightly Xywav dosing face real re-titration risk and REMS re-enrollment friction if they switch oxybates, and Epidiolex patients with seizure control established over months are similarly reluctant to change regimens, though neither friction is as strong as true technological lock-in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Jazz's rare-disease patient populations (narcolepsy, Lennox-Gastaut syndrome, Dravet syndrome, ALL/LBL) are small enough that a crowded field of competitors is uneconomical, but recent FDA approvals of generic high-sodium oxybates and Alkermes' branded Lumryz show the oxybate market is not fully closed to new entrants. |